Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

Studied

A 32-week, double-blind phase 2 trial randomized adults with type 2 diabetes to weekly CagriSema, semaglutide or cagrilintide. The primary outcome was change in HbA1c.

Who / model

The trial included 92 adults with type 2 diabetes and BMI of at least 27 who used metformin, with or without an SGLT2 inhibitor: 31 received CagriSema, 31 semaglutide and 30 cagrilintide.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

HbA1c fell 2.2 percentage points with CagriSema, 1.8 with semaglutide and 0.9 with cagrilintide. CagriSema was superior to cagrilintide, but not semaglutide, for the primary outcome. Weight fell 15.6%, versus 5.1% and 8.1%; gastrointestinal events were usually mild or moderate.

Limits

This was a small phase 2 trial with 32 weeks of follow-up; the authors called for larger, longer phase 3 studies.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary